10.1002/anie.201904096
Angewandte Chemie International Edition
COMMUNICATION
K. Rao, Y. Tzeng, Food Chem. Toxicol. 2012, 50, 2930-2936; f) C.-Y.
Yu, C.-L. J. Teng, P.-S. Hung, C.-C. Cheng, S.-L. Hsu, G.-Y. Hwang,
Y.-M. Tzeng, Eur. J. Pharmacol. 2018, 819, 16-29; g) S. Liu, C. Huang,
O. A. Bamodu, C. Lin, B. Liu, Y. Tzeng, J. Tsai, W. Lee, T. Chen,
Phytomedicine 2019, 56, 269-278.
maintaining inhibitory activity. More analogues to elucidate the
SAR and to investigate the molecular mode of action are being
synthesized and will be reported in due course. Importantly, we
confirmed the anti-hepatic CSCs effects of ovatodiolide as well
as other analogues. Isoovatodiolide proved to be more potent
than ovatodiolide by significantly decreasing the population of
hepatic CSCs and tumorspheres forming ability. Overall, the
efficient synthetic sequence, along with its exciting anti-hepatic
CSCs activity warrant the ovatodiolide scaffold as a promising
start for the discovery of novel anti-CSCs drugs.
[12] R. L. Siegel, K. D. Miller, A. Jemal, CA Cancer J. Clin. 2017, 67, 7-30.
[13] T. Yamashita, X. W. Wang, Journal of Clinical Investigation 2013, 123,
1911-1918.
[14] H. Kim, G. H. Choi, D. C. Na, E. Y. Ahn, G. Il Kim, J. E. Lee, J. Y. Cho,
J. E. Yoo, J. S. Choi, Y. N. Park, Hepatology 2011, 54, 1707-1717.
[15] a) C. Lin, O. A. Bamodu, K. Kuo, C. Huang, S. Liu, C. Wang, Y. Tzeng,
T. Chao, C. Yeh, Phytomedicine 2018, 46, 93-103; b) Y. Tu, S. Wang, L.
Fu, S. Li, Q. Guo, Y. Wu, X. Mou, X. Tong, Oncotarget 2018, 9, 3267-
3277.
Acknowledgements
[16] a) W. J. Zuercher, M. Hashimoto, R. H. Grubbs, J. Am. Chem. Soc.
1996, 118, 6634-6640; b) K. Takao, R. Nanamiya, Y. Fukushima, A.
Namba, K. Yoshida, K. Tadano, Org. Lett. 2013, 15, 5582-5585; c) M. B.
Halle, R. A. Fernandes, Rsc Adv. 2014, 4, 63342-63348; d) J. Han, F.
Li, C. Li, J. Am. Chem. Soc. 2014, 136, 13610-13613.
This work was supported by the National Natural Science
Foundation of China (NSFC) (NO. 81573282 to Y.C.; NO.
81703350 to L.W.), the National Science Fund for Distinguished
Young Scholars (NO. 81625021) to Y.C., the Fundamental
Research Funds for the Central Universities and Hundred Young
Academic Leaders Program of Nankai University. The authors
wish to express their thanks to Professor Chengfeng Xia and
Professor Shoufei Zhu for providing chiral phosphoric acid. Prof.
Pingping Tang, Prof. Zhaoyong Lu, Prof. Zunfeng Liu and Prof.
Guangxin Liang are greatly acknowledged for helpful comments.
[17] I. Chataigner, F. Zammattio, J. Lebreton, J. Villieras, Tetrahedron 2008,
64, 2441-2455.
[18] I. Paterson, G. J. Florence, A. C. Heimann, A. C. Mackay, Angew.
Chem. Int. Ed. 2005, 44, 1130-1133.
[19] J. Feng, X. Lei, R. Bao, Y. Li, C. Xiao, L. Hu, Y. Tang, Angew. Chem.
Int. Ed. 2017, 56, 16323-16327.
[20] H. Lachance, X. S. Lu, M. Gravel, D. G. Hall, J. Am. Chem. Soc. 2003,
125, 10160-10161.
[21] B. Tang, C. D. Bray, G. Pattenden, J. Rogers, Tetrahedron 2010, 66,
2492-2500.
Keywords: ovatodiolide • configuration determination • total
synthesis • cancer stem cells • diterpenoid
[22] a) P. S. Manchand, J. F. Blount, J. Org. Chem. 1977, 42, 3824-3828; b)
M. Arisawa, M. Nimura, A. Ikeda, T. Hayashi, N. Morita, Y. Momose, R.
Takeda, S. Nakanishi, Planta Med. 1986, 38-41.
[23] A. Ghantous, H. Gali-Muhtasib, H. Vuorela, N. A. Saliba, N. Darwiche,
Drug Discovery Today 2010, 15, 668-678.
[1]
[2]
A. Abbott, Nature 2006, 442, 742-743.
S. K. Singh, C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani, T. Hide, R.
M. Henkelman, M. D. Cusimano, P. B. Dirks, Nature 2004, 432, 396-
401.
[3]
[4]
[5]
P. B. Gupta, T. T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R. A.
Weinberg, E. S. Lander, Cell 2009, 138, 645-659.
M. L. Guzman, R. M. Rossi, L. Karnischky, X. J. Li, D. R. Peterson, D.
S. Howard, C. T. Jordan, Blood 2005, 105, 4163-4169.
Q. Zhang, Y. Lu, Y. Ding, J. Zhai, Q. Ji, W. Ma, M. Yang, H. Fan, J.
Long, Z. Tong, Y. Shi, Y. Jia, B. Han, W. Zhang, C. Qiu, X. Ma, Q. Li, Q.
Shi, H. Zhang, D. Li, J. Zhang, J. Lin, L. Li, Y. Gao, Y. Chen, J. Med.
Chem. 2012, 55, 8757-8769.
[6]
[7]
[8]
Y. An, W. Guo, L. Li, C. Xu, D. Yang, S. Wang, Y. Lu, Q. Zhang, J. Zhai,
H. Fan, C. Qiu, J. Qi, Y. Chen, S. Yuan, Plos One 2015, 10, e0116202.
Identifier: ACTRN12616000228482, Australian Clinical Trials, Australia.
Registrar Corp, Search orphan drug designations and approvals, U.S.
Food
and
Drug
Administration
(FDA).
[9]
ASCO, Conclusion: At well-tolerated doses, ACT001 showed
satisfactory bioavailability and preliminary evidence of anti-tumor
activity in a subset of patients, Identifier: ACT001, American Society of
[10] J. He, Essential Raw Herbal Medicine (Ed.: R. Wang, Y. He), Chinese
medicine press, China, 2015.
[11] a) H. Chang, H. Chen, O. A. Bamodu, K. Lee, Y. Tzeng, W. Lee, J. Tsai,
Toxicology in Vitro 2018, 51, 74-82; b) O. A. Bamodu, W. C. Huang, D.
T. W. Tzeng, A. Wu, L. S. Wang, C. T. Yeh, T. Y. Chao, Cancer Lett
2015, 364, 125-134; c) K. Lu, B. Wang, W. Chi, J. ChangChien, J. Yang,
H. Lee, Y. Tzeng, W. Chang, Toxins 2016, 8, 127; d) M. Liu, O. A.
Bamodu, K. Kuo, W. Lee, Y. Lin, A. T. H. Wu, M. Hsiao, Y. Tzeng, C.
Yeh, J. Tsai, M. Liu, Am. J. Chin. Med. 2018, 46, 891-910; e) Y. Liao, Y.
This article is protected by copyright. All rights reserved.